SCHEMBL4148419

SCHEMBL4148419

CC(c1nc2ccccc2[nH]1)N1CCC(O)(c2ccc(Cl)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 5/20 0.50
OPRL1 P41146 4/20 0.50
OPRD1 P41143 3/20 0.50
OPRK1 P41145 3/20 0.50
GAA P10253 1/20 0.50
DRD2 P14416 6/20 0.46
DRD4 P21917 6/20 0.46
DRD3 P35462 6/20 0.46
IDO1 P14902 1/20 0.44
HTR1A P08908 4/20 0.43
HTR2A P28223 4/20 0.43
LMNA P02545 2/20 0.43
SLC6A4 P31645 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CHRM5 P08912 1/20 0.43
ADRA2A P08913 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4150713 0.89 OPRL1 (0.50) OPRM1OPRL1OPRD1OPRK1DRD2
SCHEMBL28722124 0.76 MAPT (0.52) IDO1LMNAMEN1TSHRKMT2A
SCHEMBL4933877 0.75 BCHE (0.53) IDO1LMNAMEN1TSHRKMT2A
SCHEMBL4155864 0.74 MAPT (0.46) OPRM1OPRL1OPRD1GAAIDO1
SCHEMBL4929684 0.74 MAPT (0.50) IDO1LMNAKMT2AMLKLMAPT
SCHEMBL5962422 0.72 OPRM1 (0.63) OPRM1OPRL1OPRD1OPRK1DRD2
SCHEMBL8639468 0.67 OPRL1 (0.56) OPRM1OPRL1OPRD1OPRK1CCR3
SCHEMBL5329879 0.66 IDO1 (0.46) IDO1LMNANPC1TSHRRAB9A
SCHEMBL7327597 0.65 CYP2D6 (0.79) OPRM1OPRL1OPRD1OPRK1CYP2D6
SCHEMBL8603758 0.65 CYP2D6 (0.79) OPRM1OPRL1OPRD1OPRK1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US claimed
EP-2004613-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS AstraZeneca AB (SE) 2008-12-24 EP claimed
WO-2007115077-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2007-10-11 WO claimed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 OPRM1 141/4885OPRL1 96/4885OPRD1 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.